Affordable and Safe Health Care for All Children: Lessons Learned from the Use of Peg-asparaginase in a Developing Country

Abstract

Peg-asparaginase has widely replaced the use of conventional asparaginase in treatment of children with acute lymphoblastic leukemia in developed countries. In developing countries like India, with financial constraints being a part of clinical challenge to the treatment of cancers, uniform use of Peg-asparaginase in all children is not practically possible. However, we found by a retrospective analysis of 211 children treated for acute lymphoblastic leukemia, uniform use of this drug was feasible with indigenous techniques like storing the drug with strict cold chain maintenance and sharing the drug amongst 2 or 3 patients to reduce the burden on each family. We have not found increased rates of infection or any loss of efficacy of the drug due to prolonged storage.

Keywords: Acute lymphoblastic leukemia, allergy, fibrinogen, pancreatitis, Peg-asparaginase, thrombosis

Introduction

Pegylated *Escherichia coli* asparaginase, as part of the medical armamentarium against acute lymphoblastic leukemia (ALL) chemotherapy, has gained importance over the past few years due to its longer half-life, sustained asparagine depletion, effective central nervous system (CNS) protection, and decreased incidence of allergic reactions. However, it is still not being used widely in developing countries as innovation comes at a high cost. For developing countries like India where the children come from lower socioeconomic group with no health insurance, equity of distribution of this drug remains a challenge to the pediatric oncologists. We had developed systematic methods such as sharing the drug and strict cold chain storage up to 28 days to decrease cost of care and demonstrated improved outcomes in our cohort.

Materials and Methods

We conducted a retrospective analysis of case records of children with ALL between 1 and 18 years who were treated up front at our center from May 2007 when we started using Peg-asparaginase (Oncaspar) with the aim of studying the feasibility of using Peg-asparaginase uniformly, complications of Peg-asparaginase, and outcome in form of event-free survival. Children who had received any therapy elsewhere, children with relapsed ALL, and those lost to follow-up or defaulted treatment were excluded from the analysis.

The UK ALL 2003/2011 protocol was used uniformly. Two doses of 1000 IU/m2 of Peg-asparaginase during induction and one dose during each delayed intensification were used. One vial of Peg-asparaginase having 3750 IU/5 ml was shared among 2 or 3 children. Expenses were proportionately shared among the parents. Each new vial when opened was handled with strict aseptic precautions to prevent bacterial contamination and stored at 4°C for a maximum period of 4 weeks.

Serum fibrinogen was checked at 48 h after Peg-asparaginase injection, and if it was <100 ng/mL, 10 ml/kg of fresh frozen plasma was transfused. Data on demographic details, risk stratification as per the UK ALL criteria, and details of L-asparaginase-associated complications were documented. Disease characteristics including karyotyping and FISH and day 28 minimal residual disease (MRD) by flow cytometry were studied.

For reprints contact: reprints@medknow.com

Address for correspondence:
Dr. Dhaarani Jayaraman,
Department of Paediatric Haematology, Oncology and BMT, Apollo Cancer Institutes, No. 320, Padmam Complex, Anna Salai, Teynampet, Chennai - 600 024, Tamil Nadu, India.
E-mail: dhaarani@yahoo.com

Access this article online

Website: www.ijmpo.org

DOI: 10.4103/ijmpo.ijmpo_110_17

Results

Of the 211 children who were treated up front at our center, 150 (71.1%) were boys. The median age at presentation was 7.5 years. Based on the risk stratification, 60.2% of children were treated with regimen-A and 39.8% with regimen-B UK ALL protocol. Immunophenotyping revealed 32 T-ALL, 1 Ph + ALL, and 178 B-ALL. One child had CNS disease at diagnosis.

At the end of induction, 25% had MRD positivity and required augmented therapy. The major Peg-asparaginase-associated complications were pancreatitis in 5%, venous thrombosis in 1.4%, and allergic reactions in 2% children. Those who had significant grade 3 or 4 pancreatitis or thrombotic events were not challenged again with the drug. The incidence of venous thrombosis was clearly low at 1.4% as compared to published data from the UK MRC trials at 3.2%.

A total of 211 children have shared 130 vials of Peg-asparaginase. An effective saving of 60% could be made for each child with no major side effects due to prolonged storage.

Event-free survival in our cohort was 88% compared to the UK MRC data. Relapse rate in our cohort was 10.2%, with medullary relapse being the most common. CNS relapse was noted in five children, including three with combined CNS and medullary relapse.

Discussion

Peg-asparaginase is formed by covalent linking of 5000 dalton units of monomethoxypolyethylene glycol to E. coli asparaginase. Binding preserves the enzyme activity but decreases immunogenicity of the protein. The pharmacokinetic studies have shown slow rise and sustained blood levels of the drug, making it more effective by causing prolonged and sustained asparagine depletion, thereby depriving the leukemic cells of this essential amino acid and causing enhanced cell kill.[1]

Major toxicities associated with asparaginase include hyperglycemia, pancreatitis, allergic reactions, transaminitis, and venous thrombosis. The incidence of each of these in our cohort is tabulated in Table 1. The incidence of allergic reactions was low; however, asparagine antibody level/silent inactivation was not studied in our cohort. Venous thrombosis due to Peg-asparaginase is due to the decreased levels of antithrombin importantly, also contributed by the decreased levels of plasminogen activator. Serum fibrinogen also decreases in parallel with antithrombin level and hence serves as a surrogate marker of coagulopathy.[2,3] In our cohort, we found that 25% children had critically low levels of fibrinogen (<100 ng/mL) and were transfused with fresh frozen plasma. There is a significant decrease in the incidence of venous thrombosis at 1.4% compared to the UK MRC data at 3.2% (P = 0.0017). This could probably be due to the early correction of asymptomatic coagulopathy. Transaminitis was noted in 2.6% children, not requiring treatment interruption. The incidence of pancreatitis is high in our cohort.

Due to the high cost, it is not a standard practice to use Peg-asparaginase for all children in most of the centers in India. We have developed methods to universalize its use for all children despite the socioeconomic strata. Peg-asparaginase is stored at 2–4°C for maximum period of 4 weeks and handled with strict aseptic precautions. Each vial of 3750 units/mL has been shared among 3–4 children. The cost of each vial was 2200 USD, and if we had used a separate vial for each child, the total amount would have been 671,000 USD. However, 50%–60% savings could be done for each child by sharing the drug. It is the need of the hour to develop indigenous strategies to universalize standard treatment in developing countries with varied socioeconomic distribution of the patient population.[4] We documented an event-free survival of 88%, which is higher than other centers in India with the use of Peg-asparaginase being the backbone of ALL therapy only at our center.

Conclusion

The use of Peg-asparaginase is feasible in children from developing countries despite the social and financial issues. The incidence of deep vein thrombosis can clearly be reduced by monitoring serum fibrinogen. Peg-asparaginase could be safely stored up to 4 weeks and effectively shared to significantly cut down burden on individual family and deliver standard care to all children. The low toxicity profile and excellent clinical efficacy make it the most important way forward to improve outcomes and reduce relapses in our country.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Table 1: Toxicity profile of peg-asparaginase in our cohort

<table>
<thead>
<tr>
<th>Complications</th>
<th>Incidence</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low fibrinogen</td>
<td>53 (25.1%)</td>
<td>Transfused with ffp</td>
</tr>
<tr>
<td>Deep vein thrombosis</td>
<td>3 (1.4%)</td>
<td>I-Cvt, 1 – portal vein thrombosis</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>10 (4.7%)</td>
<td>Nci grade 3 – 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nci grade 4 – 2</td>
</tr>
<tr>
<td>Allergic reactions</td>
<td>4 (1.9%)</td>
<td>Grade 1 – 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grade 2 – 2</td>
</tr>
</tbody>
</table>
References


